Xin Jing Bao·2025-12-31 11:42Core Viewpoint - The article discusses the strategic development goals and initiatives of the company, 诺诚健华, in response to the central economic work meeting's emphasis on expanding domestic demand and optimizing supply in the context of the 2026 economic landscape [1][3]. Group 1: Company Initiatives - The company has achieved significant milestones, including a partnership with Zenas worth over $2 billion, marking a record in the field of self-immune small molecules in China [1]. - Two innovative drugs have been approved for market launch, including the first CD19 monoclonal antibody for treating diffuse large B-cell lymphoma and the first domestically developed TRK inhibitor [2]. - The company plans to launch five to six innovative drugs and develop five to ten differentiated clinical candidates by 2026, aiming to accelerate the globalization process and enhance its core competitiveness in innovative drug development [3]. Group 2: Strategic Development Goals - By 2026, the company aims to leverage "Chinese originality" and a "global vision" to embark on a new decade of growth, focusing on innovation and global market expansion [3]. - The company intends to strengthen its overseas team capabilities and achieve globalization for three to four products, enhancing its core competitiveness in innovative drug development from China to the global market [3]. - The company will maintain a passion for entrepreneurial innovation and a keen insight to drive rapid development in a challenging environment [3].